Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.
Publication/Presentation Date
2-1-2018
Abstract
Administration of granulocyte colony-stimulating factor (G-CSF) after autologous peripheral blood stem cell transplantation (PBSCT) is generally recommended to reduce the duration of severe neutropenia; however, data regarding the optimal timing of G-CSFs post-transplantation are limited and conflicting. This retrospective study was performed at NewYork-Presbyterian/Weill Cornell Medical Center between November 5, 2013, and August 9, 2016, of adult inpatient autologous PBSCT recipients who received G-CSF empirically starting on day +5 (early) versus on those who received G-CSF on day +12 only if absolute neutrophil count (ANC) was
Volume
24
Issue
2
First Page
288
Last Page
293
ISSN
1523-6536
Published In/Presented At
Singh, A. D., Parmar, S., Patel, K., Shah, S., Shore, T., Gergis, U., Mayer, S., Phillips, A., Hsu, J. M., Niesvizky, R., Mark, T. M., Pearse, R., Rossi, A., & van Besien, K. (2018). Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 24(2), 288–293. https://doi.org/10.1016/j.bbmt.2017.10.026
Disciplines
Medicine and Health Sciences
PubMedID
29061534
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article